Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series
- PMID: 22713449
- DOI: 10.1177/120347541201600316
Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series
Abstract
Background: Intralesional methotrexate (IL-MTX) is an effective treatment for keratoacanthoma.
Objective: We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate.
Methods: All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed.
Results: Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur.
Limitations: The follow-up period was short, and there was no histologic confirmation of the initial diagnosis.
Conclusion: IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.
Similar articles
-
Intralesional methotrexate versus 5-flurouracil in the treatment of keratoacanthoma.Arch Dermatol Res. 2024 Jun 15;316(7):400. doi: 10.1007/s00403-024-03139-1. Arch Dermatol Res. 2024. PMID: 38878177 Free PMC article. Clinical Trial.
-
Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature.J Am Acad Dermatol. 2007 Jun;56(6):989-93. doi: 10.1016/j.jaad.2006.12.017. J Am Acad Dermatol. 2007. PMID: 17504715 Review.
-
[Intralesional infusion of methotrexate as neoadjuvant therapy improves the cosmetic and functional results of surgery to treat keratoacanthoma: results of a randomized trial].Actas Dermosifiliogr. 2011 Oct;102(8):605-15. doi: 10.1016/j.ad.2011.03.013. Epub 2011 Jul 13. Actas Dermosifiliogr. 2011. PMID: 21742301 Clinical Trial. Spanish.
-
Management of Keratoacanthoma: 157 Tumors Treated With Surgery or Intralesional Methotrexate.Dermatol Surg. 2019 Jul;45(7):877-883. doi: 10.1097/DSS.0000000000001739. Dermatol Surg. 2019. PMID: 30608293
-
Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature.J Drugs Dermatol. 2019 Jul 1;18(7):693-696. J Drugs Dermatol. 2019. PMID: 31334929 Review.
Cited by
-
Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin.JAAD Case Rep. 2016 Jul 14;2(3):269-71. doi: 10.1016/j.jdcr.2016.05.007. eCollection 2016 May. JAAD Case Rep. 2016. PMID: 27486591 Free PMC article. No abstract available.
-
Intralesional methotrexate versus 5-flurouracil in the treatment of keratoacanthoma.Arch Dermatol Res. 2024 Jun 15;316(7):400. doi: 10.1007/s00403-024-03139-1. Arch Dermatol Res. 2024. PMID: 38878177 Free PMC article. Clinical Trial.
-
Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma.Cancers (Basel). 2023 Dec 28;16(1):158. doi: 10.3390/cancers16010158. Cancers (Basel). 2023. PMID: 38201585 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
